These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24505199)

  • 21. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
    Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
    Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
    Higashiyama T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ohji M
    Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
    Sohn HJ; Han DH; Lee DY; Nam DH
    Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group.
    Wu L; Arevalo JF; Hernandez-Bogantes E; Regatieri CV; Roca JA; Farah ME
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):366-71. PubMed ID: 23215543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.
    Carneiro AM; Costa R; Falcão MS; Barthelmes D; Mendonça LS; Fonseca SL; Gonçalves R; Gonçalves C; Falcão-Reis FM; Soares R
    Acta Ophthalmol; 2012 Feb; 90(1):e25-30. PubMed ID: 21958440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.
    Hufendiek K; Hufendiek K; Panagakis G; Helbig H; Gamulescu MA
    Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome.
    Kim JM; Kim JH; Chang YS; Kim JW; Kim CG; Lee DW
    Korean J Ophthalmol; 2017 Jun; 31(3):240-248. PubMed ID: 28471100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion.
    Ramezani A; Esfandiari H; Entezari M; Moradian S; Soheilian M; Dehsarvi B; Yaseri M
    Graefes Arch Clin Exp Ophthalmol; 2012 Aug; 250(8):1149-60. PubMed ID: 22331147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration.
    Aslankurt M; Aslan L; Aksoy A; Erden B; Cekiç O
    Eur J Ophthalmol; 2013; 23(4):553-7. PubMed ID: 23516253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.
    Lim JY; Lee SY; Kim JG; Lee JY; Chung H; Yoon YH
    Acta Ophthalmol; 2012 Feb; 90(1):61-7. PubMed ID: 20337606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
    Veritti D; Sarao V; Lanzetta P
    J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.
    Sato T; Wada K; Arahori H; Kuno N; Imoto K; Iwahashi-Shima C; Kusaka S
    Am J Ophthalmol; 2012 Feb; 153(2):327-333.e1. PubMed ID: 21930258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.
    Sohn EH; He S; Kim LA; Salehi-Had H; Javaheri M; Spee C; Dustin L; Hinton DR; Eliott D
    Arch Ophthalmol; 2012 Sep; 130(9):1127-34. PubMed ID: 22965588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal bevacizumab for radiation-induced cystoid macular oedema in patients with nasopharyngeal carcinoma: a clinical series.
    Subrayan V; Khaw KW; Peyman M; Koay AC; Tajunisah I
    Ophthalmologica; 2013; 229(4):208-11. PubMed ID: 23548379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
    Lee SJ; Koh HJ
    Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.